Grasustek (Pegfilgrastim)

Grasustek is indicated for specific hematologic support in patients receiving myelosuppressive therapy.

• Prevention of chemotherapy‑induced neutropenia in adult patients.
• Reduction of the duration of severe neutropenia following cytotoxic chemotherapy.
• Mobilization of peripheral blood stem cells for autologous transplantation.
• Support of patients with high‑risk regimens where neutrophil recovery is critical.
• Use in clinical protocols that require rapid neutrophil count recovery.

The safety profile of pegfilgrastim includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Bone pain, often in the back, hips, or legs.
• Injection‑site reactions such as redness, swelling, or itching.
• Mild fever or flu‑like symptoms.
• Fatigue or weakness.
• Nausea or vomiting.
• Headache.

Serious

• Splenic rupture, a rare but potentially life‑threatening event.
• Acute respiratory distress syndrome (ARDS) or severe pulmonary toxicity.
• Severe allergic reactions, including anaphylaxis and angioedema.

Clinicians should evaluate patient history and monitor for specific conditions before initiating Grasustek therapy.

• Assess for prior splenic injury or known splenomegaly.
• Use caution in patients with a history of severe allergic reactions to biologics.
• Evaluate renal or hepatic impairment, as dose adjustments may be required.
• Monitor complete blood counts regularly to detect unexpected leukocytosis or thrombocytopenia.
• Avoid concurrent use with other colony‑stimulating factors unless medically justified.
• Consider postponing treatment in patients with active infections.
• Discuss potential bone pain management strategies with patients.

Pegfilgrastim may interact with other medications or biologic agents, influencing efficacy or safety.

Avoid

• Concurrent administration of other granulocyte colony‑stimulating factors (e.g., filgrastim) without clear clinical indication.
• Use with live vaccines during the period of neutrophil recovery, as immune response may be altered.

Use with caution

• Chemotherapeutic agents that cause profound myelosuppression, requiring close monitoring of neutrophil counts.
• Corticosteroids, which may mask signs of infection.
• Antimicrobial prophylaxis agents, to ensure appropriate timing relative to pegfilgrastim dosing.
• Immunosuppressive therapies, as combined effects on the immune system may increase infection risk.